Results 51 to 60 of about 29,580 (292)

Intermittent and Short-Term Empirical Ruxolitinib Regimen for Steroid-Refractory Flareups of Fibrodysplasia Ossificans Progressiva. [PDF]

Pharmacol Res Perspect
ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare genetic disorder with inflammation‐related flare‐ups resulting in catastrophic heterotopic ossification (HO). Janus‐associated kinase (JAK) inhibitors may have had a blocking effect on bone formation in controlling FOP flare‐ups by blocking multiple inflammatory signaling pathways ...
Chen RL, Yang TH, Wang YH, Shaw JJ, Chen LY.   +4 more
europepmc   +2 more sources

Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK/STAT1 signaling pathway

FEBS Open Bio, EarlyView.
We found that during chemotherapy‐induced alopecia (CIA), Sonic hedgehog (Shh) expression significantly decreased in hair follicle Shh+ cells, whereas the Janus‐activated kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway was markedly activated.
Ruifang Fan, Jingling Huang, Xiang Lin, Tingjiao Lan, Yuli Tang, Ling Sun, Guixuan Zhou   +6 more
wiley   +1 more source

Wedelolactone, a Novel TLR2 Agonist, Promotes Neutrophil Differentiation and Ameliorates Neutropenia: A Multi‐Omics Approach to Unravel the Mechanism

Advanced Science, EarlyView.
Wedelolactone (WED), a natural TLR2 agonist, promotes neutrophil differentiation and enhances bactericidal function, offering a potential therapeutic strategy for neutropenia. Using a multi‐omics approach, this study reveals that WED activates the TLR2/MEK/ERK pathway, upregulating key transcription factors (PU.1, CEBPβ) to drive neutrophil development.
Long Wang, Zhichao Li, Tianci Hu, Qinyao Li, Linwei Zhang, Xinyue Mei, Xiao Qi, Sheng Liu, Weijie Kong, Jiesi Luo, Anguo Wu, Feihong Huang, Sirui Li, Shuang Dai, Chunxiang Zhang, Rong Li, Jianming Wu   +16 more
wiley   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

Cancer Immunology, Immunotherapy
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by marrow fibrosis, splenomegaly, constitutional symptoms and cytopenia with a proinflammatory and profibrotic cytokine phenotype involving the JAK-STAT pathway.
Sara Villar, Emmanuel Curis, Marie-Hélène Schlageter, Nelly Bosselut, Amandine Charbonnier, Marie-Thérèse Rubio, Pascal Turlure, Hélène Labussière, Jacques-Olivier Bay, Jérome Cornillon, Laure Vincent, Corentin Orvain, Jean-Jacques Kiladjian, David Michonneau, Gérard Socié, Marie Robin   +15 more
doaj   +1 more source

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms. [PDF]

EJHaem
ABSTRACT Background Aquagenic pruritus (AP) is a common and distressing symptom in myeloproliferative neoplasm (MPN) patients. Methods This study assessed cytoreductive therapy effectiveness using data from 489 patients in the OBENE Observatory (NCT02897297). AP severity was tracked regularly after diagnosis.
Gall-Ianotto CL, Civi L, Pan-Petesch B, Herbreteau L, Rio L, Lambert WC, Misery L, Lippert E, Ianotto JC.   +8 more
europepmc   +2 more sources

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +2 more sources

Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis. [PDF]

EJHaem
ABSTRACT Introduction Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort ...
Blanco-Sánchez A, Ayala R, Carreño-Tarragona G, Colmenares R, López-Muñoz N, Sáez A, Palacios-Berraquero ML, Hernández J, Martínez-López J.   +8 more
europepmc   +2 more sources

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome [PDF]

, 2023
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata Monika Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michèle Cavo, Massimiliano Bonifacio, Giuseppe A. Palumbo   +39 more
openalex   +1 more source